Duchenne UK, the Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) announce a joint grant of $686,500 to Dr William Evans (principal investigators) at the University of California, Berkeley to use a novel method to measure changes in total muscle mass in Duchenne muscular dystrophy patients through biomarkers in urine samples.

These biomarkers may represent a better way to assess new treatments for Duchenne while reducing invasive muscle biopsies or expensive MRI scans that are not available at all clinical trial sites, according to a media release from the Muscular Dystrophy Association.

Initial Study Results

In 2018, Duchenne UK (with Solid Biosciences) made a grant of $162,600 to Duke University and University of California, Berkeley for an initial study of new biomarkers for Duchenne.  The initial study was carried out with 10 boys with Duchenne and 9 healthy boys of a similar age. Now, in a joint collaboration, PPMD, MDA and Duchenne UK are supporting the next phase of research, in the hopes of reproducing these results in a larger study consisting of approximately 150 boys with Duchenne. 

“The team successfully demonstrated that their method provided an accurate measurement of functional muscle mass in infants, children, and adults. Most important, the study showed that this method worked well in patients with Duchenne.”

— Emily Crossley, Joint Cofounder and CEO Duchenne UK

Recent Results Could Provide Hope

“If this study is successful, a completely non-invasive, new method of measuring the amount of functional muscle in boys with Duchenne based on a single urine sample may be made possible – signifying a much faster way to assess new treatments for Duchenne and other muscle-wasting diseases,” Crossley adds.

“We are excited to be working together with MDA and Duchenne UK to support the development of a novel biomarker. Biomarkers are a key part of unlocking our understanding of how an individual is changing and responding to investigational therapeutics.”

— Eric Camino, PPMD’s Director of Research and Clinical Innovation

“We know how much families sacrifice to participate in clinical trials. We are happy to join with Duchenne UK and PPMD to support the development of new research tools that may ease that burden while accelerating research.

“This may increase the likelihood that individuals with Duchenne participate in clinical trials, and help speed treatments and cures. It would also reduce the need for biopsies and MRI’s of patients in clinical trials.”

— Dr Sharon Hesterlee, Chief Research Officer, MDA

[Source(s): Muscular Dystrophy Association, PR Newswire]

Related Content:
PPMD Presents 1-Year Newborn Duchenne Screening Project Update
Funding Aims to Advance Development of Duchenne Bone Wastage Therapy
Cystic Fibrosis Gene’s Duchenne Effect